# US 8,465,948 B2 · Long-acting veterinary polypeptides and methods of producing and administering same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,465,948 B2 - Document ID: US8465948B2 - Status: Granted - Kind: B2 - Application number: 13/192,542 - Filed: 2011-07-28 - Published: 2012-01-05 - Granted: 2013-06-18 - Earliest claimed: 2006-02-03 - Assignees: Prolor Biotech Ltd. - Applicants: Fuad Fares; Udi Eyal Fima - Inventors: Fuad Fares; Udi Eyal Fima - Web page: https://patentgrep.com/patent/US8465948B2 ## CPC - C07K 14/505: Erythropoietin [EPO] - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 3/04: Anorexiants; Antiobesity agents - A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH - A61P 7/00: Drugs for disorders of the blood or the extracellular fluid - A61P 7/06: Antianaemics - A61P 31/12: Antivirals - A61P 35/00: Antineoplastic agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07K 14/555: Interferons [IFN] - C07K 14/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH] - C07K 14/61: Growth hormone [GH], i.e. somatotropin - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K 2319/00: Fusion polypeptide - C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed. ## Claims ### Claim 1 A polynucleotide consisting of a nucleic acid encoding a polypeptide, said polypeptide consisting of a non-human growth hormone, one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said non-human growth hormone, and two chorionic gonadotrophin CTPs attached to the carboxy terminus of said non-human growth hormone, wherein said polypeptide optionally comprises a signal peptide attached to the amino terminus of said one CTP, and wherein at least one CTP is optionally attached to said non-human growth hormone via a linker. ### Claim 2 (depends on 1) The polynucleotide of claim 1, wherein at least one CTP is glycosylated. ### Claim 3 (depends on 1) The polynucleotide of claim 1, wherein at least one CTP is truncated. ### Claim 4 (depends on 1) The polynucleotide of claim 1, wherein at least one CTP is attached to said non-human growth hormone via a linker. ### Claim 5 (depends on 4) The polynucleotide of claim 4, wherein said linker is a peptide bond. ### Claim 6 (depends on 1) The polynucleotide of claim 1, wherein the sequence of at least one CTP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18. ### Claim 7 (depends on 1) The polynucleotide of claim 1, wherein said polypeptide further comprises a signal peptide attached to the amino terminus of said one CTP. ### Claim 8 (depends on 1) An expression vector comprising the polynucleotide of claim 1. ### Claim 9 (depends on 8) An isolated cell comprising the expression vector of claim 8. ### Claim 10 (depends on 8) A composition comprising the expression vector of claim 8 and a pharmaceutically acceptable carrier. ### Claim 11 A method of producing a non-human growth hormone with an improved biological half life in an isolated cell, comprising the step of transfecting said cell with an expression vector comprising a polynucleotide consisting of a nucleic acid encoding a polypeptide, said polypeptide consisting of a non-human growth hormone, one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said non-human growth hormone, and two chorionic gonadotrophin CTPs attached to the carboxy terminus of said non-human growth hormone, wherein said polypeptide optionally comprises a signal peptide attached to the amino terminus of said one CTP, and wherein at least one CTP is optionally attached to said non-human growth hormone via a linker, thereby producing a non-human growth hormone with an improved biological half life in an isolated cell. ### Claim 12 (depends on 11) The method of claim 11, wherein the sequence of at least one CTP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18. ### Claim 13 (depends on 11) The method of claim 11, wherein said polypeptide further comprises a signal peptide attached to the amino terminus of said one CTP. ### Claim 14 (depends on 11) The method of claim 11, wherein at least one CTP is glycosylated. ### Claim 15 (depends on 11) The method of claim 11, wherein at least one CTP is truncated. ### Claim 16 (depends on 11) The method of claim 11, wherein at least one CTP is attached to said non-human growth hormone via a linker. ### Claim 17 (depends on 16) The method of claim 16, wherein said linker is a peptide bond.